News 
Market Data 
Discover
Replies to post #206260 on Biotech Values
11/21/16 8:31 PM
MY ONLY LONG !!!! Don't trust Longs. Krensavage says it's GREAT and I am IN..
— Marc Cohodes (@AlderLaneEggs) November 22, 2016
11/22/16 8:50 AM
Dr. Russell currently serves as Chief Medical Officer at Innocoll Holdings, Plsc., a global, specialty pharmaceutical company, where she leads the clinical development programs, and medical and regulatory affairs groups. Prior, she held executive management positions at TetraLogic Pharmaceuticals, where she held the role of Chief Operating Officer from 2013 through 2016, and at Teva Pharmaceuticals, where she was Senior Vice president and Global Head of Research and Development from 2011-2012. At Teva, she led a team of over 1,500 and was responsible for all aspects of global drug development. Earlier in her career, she spent over 10 years at Cephalon, Inc. where she held positions of increasing responsibility from 2000 -2011, most recently serving as Executive Vice President and Chief Medical Officer.
Dr. Russell currently serves on the Boards of Directors of AMAG Pharmaceuticals, Inc. and Endocyte Pharmaceuticals, Inc., public biotechnology companies, and Melmark, Inc., a non-profit organization serving adults and children with severe intellectual and physical disabilities.
12/09/16 1:01 PM
12/19/16 8:59 AM
I expect annual worldwide sales of G/P to peak at $4B in 2020. ENTA's annual royalty on G/P sales is tiered from 5% to 10%, where each tier is defined by undisclosed sales thresholds, so let's say ENTA gets an average 7% royalty rate in 2020. 7% of $4B = $280M. Say operating expenses and taxes consume $80M, leaving $200M of net profit.
